Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q4 2016 call → NOWe need answer YES or NO based on transcript. Need determine if management describes company currently living through defined waiting period paying out of pocket, with cost now, benefit not yet, end near-dated visible, and main work. Let's parse. The call is about Q4 2016. They discuss lung cancer program, Opdivo, etc. Key: They had regulatory update, not pursuing expedited pathway in front-line lung. They have broad program. They mention "we are not able to provide specific details". They talk about investments in I-O, R&D. But is there a specific "waiting period" with current costs and future benefit? They mention "we expect to keep total operating expenses roughly flat through 2020 compared to 2016, but with an increase in R&D this year." That's investment. But not a defined waiting period with near-dated event. They mention "we are focused on defending our position" in lung, "increasing competitive pressure". Not a self-funded gap. They mention "we have four combination front-line lung studies ongoing" and "optionality". But no specific near-dated event like data readout? They mention "we expect to see important early data readouts, including IDO, GITR, and LAG-3." But not a single defined waiting period. Question asks: "On this call, does management describe the company as CURRENTLY LIVING THROUGH A DEFINED WAITING PERIOD IT IS PAYING FOR OUT OF ITS OWN POCKET — that is, does management convey that the company is presently carrying real, ongoing cash or earnings cost for something whose benefit has not arrived yet, AND that the end of that waiting period is a specific, near-dated event the company can already see and is already working toward?" Need answer YES only if all three. Let's examine. Management discusses "we have a broad front-line lung cancer program which we expanded and strengthened over the last several months. We have four combination front-line lung studies that are ongoing." They are investing in R&D. But do they say they are paying now for something not yet earning? R&D is always cost now for future. But is there a specific near-dated event? They mention "we expect to see important early data readouts, including IDO, GITR, and LAG-3." But not a specific date. Also "Later this year, we expect early data in house from assets in systemic lupus, NASH, and psoriasis." That's pipeline.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.